Cerus Corporation reiterated product revenue guidance for the full year 2024. The company expects full-year 2024 product revenue will be in the range of $172 million to $175 million. Included in this range is full-year 2024 INTERCEPT Fibrinogen Complex revenue guidance between $8 million to $10 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.74 USD | +1.16% | +4.82% | -19.44% |
May. 02 | Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M | MT |
Apr. 12 | Craig-Hallum Starts Cerus With Buy Rating, $5 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.44% | 318M | |
+9.07% | 125B | |
-8.61% | 10.63B | |
+2.17% | 8.92B | |
+23.48% | 7.39B | |
+32.13% | 4.96B | |
+7.84% | 3.41B | |
-6.94% | 3.04B | |
-5.07% | 2.23B | |
-4.22% | 2.13B |
- Stock Market
- Equities
- CERS Stock
- News Cerus Corporation
- Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024